Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2010 | Volume: 6 | Issue: 4 | Page No.: 338-345
DOI: 10.3923/ijp.2010.338.345
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

A Systematic Account of Pathogenesis, Diagnosis and Pharmacotherapy of Metabolic Syndrome: Things We Need to Know

R. Mahajan, K. Gupta and V. Kapoor

Abstract:
Metabolic Syndrome (MS) is a collection of risk factors including insulin resistance, central obesity, hypertension and dyslipidemia and itself is a risk factor for coronary artery disease. In recent times, its prevalence is on a rise in obese children too. Many working criteria for diagnosing MS are doing-the-round; given by World Health Organization, Adult Treatment Panel 3 and American Association of Clinical Endocrinologists. Risk factors involved in the pathogenesis of MS are many-fold; accordingly pharmacotherapy of MS is also multifacet. This review article is an account of pathogenesis, diagnosis and available treatment options in MS with a brief account of future prospect.
PDF Fulltext XML References Citation Report Citation
 RELATED ARTICLES:
  •    Antihyperglycemic, Antihyperlipidemic and Cardioprotective Profile of Bromocriptine, Glibenclamide and Metformin Combination in Dexamethasone-induced Hyperglycemic Rats
  •    Risk Factors of Coronary Artery Disease in Affected Patients With and Without Psoriasis: The First Case-control Study in the Literature
  •    Abnormal Serum Lipid Profile and Smoking are Associated with Plaque-type Psoriasi: A Case Control Study
  •    Effect of L-Arginine on Some Biochemical Markers of Metabolic Syndrome Associated with Brain Function in Female Wistar Rats
  •    Contribution of Information and Communication Technology to the Prevalence of Obesity and Elevated Blood Pressure among Secondary School Students in Nigeria
How to cite this article:

R. Mahajan, K. Gupta and V. Kapoor, 2010. A Systematic Account of Pathogenesis, Diagnosis and Pharmacotherapy of Metabolic Syndrome: Things We Need to Know. International Journal of Pharmacology, 6: 338-345.

DOI: 10.3923/ijp.2010.338.345

URL: https://scialert.net/abstract/?doi=ijp.2010.338.345

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

Curve Bottom